Cara Therapeutics to Present at the the 2021 Cantor Virtual Global Healthcare Conference

Rhea-AI Summary

Cara Therapeutics, Inc. (Nasdaq: CARA) will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 3:20 p.m. ET. The event will feature Derek Chalmers, Ph.D., D.Sc., President and CEO. A live webcast can be accessed through the company's website, with an archived recording available for 30 days. Cara focuses on developing therapies for pruritus by targeting peripheral kappa opioid receptors. Their leading product, KORSUVA, was approved by the FDA on August 23, 2021, to treat pruritus in adults undergoing hemodialysis.

STAMFORD, Conn., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 3.20 p.m. ET.

A live webcast of the fireside chat can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. KORSUVA Injection was approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP ) in adults undergoing hemodialysis on August 23, 2021. Oral KORSUVA has completed Phase 2 trials for the treatment of pruritus in patients with CKD and atopic dermatitis and is currently in Phase 2 trials in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.

MEDIA CONTACT:
Claire LaCagnina
6 Degrees
315-765-1462
clacagnina@6degreespr.com

INVESTOR CONTACT:
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@SternIR.com

FAQ

When will Cara Therapeutics participate in the Cantor Virtual Global Healthcare Conference?

Cara Therapeutics will participate in the Cantor Virtual Global Healthcare Conference on September 28, 2021, at 3:20 p.m. ET.

Who will represent Cara Therapeutics at the conference?

Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will represent Cara Therapeutics at the conference.

How can I watch the Cara Therapeutics fireside chat?

The fireside chat can be viewed live on the Cara Therapeutics website under 'Events & Presentations' in the News & Investors section.

What is KORSUVA and when was it approved?

KORSUVA is a product developed by Cara Therapeutics for treating pruritus. It was approved by the FDA on August 23, 2021.

What conditions is Cara Therapeutics focusing on for KORSUVA?

Cara Therapeutics is focusing on chronic kidney disease-related pruritus and pruritus in patients with atopic dermatitis.